Bryleos
Bryleos is a clinical-stage therapeutics company focused on developing interventions for neurological diseases of aging. Utilizing advanced technologies like artificial intelligence and machine learning, Bryleos aims to overcome traditional barriers in drug development, leading to faster market entry and reduced costs. Their flagship product, BRY101, is a first-in-class oral therapeutic that targets multiple factors of neurological aging, including mitochondrial dysfunction and neuroinflammation. The company differentiates itself through its innovative Lath Mized™ Green Platform Technology, which enhances the bioavailability and stability of therapeutic compounds while minimizing environmental impact. With a strong focus on cellular health, Bryleos is positioned to address urgent health challenges related to neurodegenerative diseases.
Bryleos
Bryleos is a clinical-stage therapeutics company focused on developing interventions for neurological diseases of aging. Utilizing advanced technologies like artificial intelligence and machine learning, Bryleos aims to overcome traditional barriers in drug development, leading to faster market entry and reduced costs. Their flagship product, BRY101, is a first-in-class oral therapeutic that targets multiple factors of neurological aging, including mitochondrial dysfunction and neuroinflammation. The company differentiates itself through its innovative Lath Mized™ Green Platform Technology, which enhances the bioavailability and stability of therapeutic compounds while minimizing environmental impact. With a strong focus on cellular health, Bryleos is positioned to address urgent health challenges related to neurodegenerative diseases.